Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-17T09:02:12.707Z Has data issue: false hasContentIssue false
  • English
  • Français

Myocardial protection by nicorandil during open-heart surgery under cardiopulmonary bypass

Published online by Cambridge University Press:  24 May 2006

N. K. Chinnan ,
G. D. Puri  and
S. K. S. Thingnam
N. K. Chinnan
Affiliation:
Post Graduate Institute of Medical Education and Research (PGIMER), Department of Anaesthesia and Intensive Care, Chandigarh, India
G. D. Puri
Affiliation:
Post Graduate Institute of Medical Education and Research (PGIMER), Department of Anaesthesia and Intensive Care, Chandigarh, India
S. K. S. Thingnam
Affiliation:
Post Graduate Institute of Medical Education and Research (PGIMER), Department of Cardiothoracic and Vascular Surgery, Chandigarh, India
Get access

Extract

Summary

Background: To evaluate the myocardial protective effect of nicorandil when used as an adjuvant to cold hyperkalaemic cardioplegia in open-heart surgery. Methods: Patients who underwent surgery under cardiopulmonary bypass (CPB) for mitral valve replacement (MVR, 23 patients) or coronary artery bypass grafting (CABG, 24 patients) were entered in a double-blind study. The patients were randomized to a nicorandil Group (N) or placebo Group (P). Nicorandil 0.1 mg kg−1 (Group N), or normal saline (Group P), were administered at three time points: (1) after aortic cannulation, but prior to going on CPB, (2) 5 min before aortic cross-clamping and (3) 5 min before reperfusion. The following variables were studied: (a) time until electromechanical arrest after cardioplegia administration (Tarrest), (b) time until return of electromechanical activity after aortic cross-clamp removal (Trecovery), (c) incidence of postoperative myocardial infarction or low output syndromes (d) dysrhythmias requiring intervention after aortic cross-clamp removal and (e) haemodynamic changes after nicorandil administration. Results: The Tarrest after cardioplegia administration was significantly faster in nicorandil group in both MVR and CABG patients (P < 0.05), but Trecovery did not differ significantly. The incidence of postoperative serum CK-MB > 75 IU L−1 in MVR patients was significantly lower in the Group N than in placebo patients (P < 0.05). However, in CABG patients there was no such significant difference. The incidence of dysrhythmias requiring intervention after aortic cross-clamp removal was also less in Group N. Administration of 0.1 mg kg−1 boluses of nicorandil did not cause significant haemodynamic changes or precipitate dysrhythmias in any patient. Conclusion: Nicorandil enhances the myocardial protective effect of cold hyperkalaemic cardioplegia in cardiac surgery patients.

Keywords

CARDIAC SURGERYNICORANDILMYOCARDIAL ISCHAEMIA, preventionCARDIOPULMONARY BYPASS
Type
EACTA Original Article
Information
European Journal of Anaesthesiology , Volume 24 , Issue 1 , January 2007 , pp. 26 - 32
Copyright
© 2006 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Das SN, Chauhan S, Saxena N. Myocardial preservation during cardiac surgery. Ann Cardiac Anaesth 2002; 5: 25–32.Google Scholar
Mangano CM, Hill L, Cartwright CR, Hindman BJ. Cardiopulmonary bypass and the anesthesiologist. In: Kaplan JA, ed. Cardiac Anesthesia, 4th edn. Philadelphia: WB Saunders Company, 1999: 1061–1112.
Cohen G, Borger MA, Weisel RD, Rao V. Intraoperative myocardial protection: current trends and future perspectives. Ann Thorac Surg 1999; 68: 1995–2001.Google Scholar
Chambers DJ, Hearse DJ. Developments in cardioprotection: ‘polarized arrest’ as an alternative to ‘depolarized’ arrest. Ann Thorac Surg 1999; 68: 1960–1966.Google Scholar
Gundry SR, Kirsh MM. A comparison of retrograde vs. anterograde cardioplegia in presence of coronary artery obstruction. Ann Thorac Surg 1984; 38: 124–127.Google Scholar
Talwalkar NG, Lawrie GM, Earle N, DeBakey ME. Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery? Chest 1999; 115: 135–139.Google Scholar
Tian G, Xiang B, Dai G et al. Retrograde cardioplegia. J Thorac Cardiovasc Surg 2003; 125: 872–880.Google Scholar
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–1136.Google Scholar
Kersten JR, Gross GJ, Pagel PS, Warltier DC. Activation of ATP-regulated potassium channels: mediation of cellular and organ protection. Anesthesiology 1998; 88: 495–513.Google Scholar
Tomai F, Crea F, Chiariello L, Gioffre PA. Ischemic preconditioning in humans. Models, mediators, and clinical relevance. Circulation 1999; 100: 559–563.Google Scholar
Lopez JR, Jahangir R, Jahangir A, Shen WK, Terzic A. Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: possible implications in cardioplegia. J Thorac Cardiovasc Surg 1996; 112: 820–831.Google Scholar
Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM. Cardioprotective effects of nicorandil. J Cardiovasc Pharmacol 1992; 20 (Suppl 3): S22–S28.Google Scholar
Jha RJ. Cardioprotective effects of nicorandil. Cardiol Today 1998; 4: 284–287.Google Scholar
Markham A, Plosker GL, Goa KL. Nicorandil: an updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60: 955–974.Google Scholar
Hayashi Y, Sawa Y, Ohtake S, Nishikawa M, Ichikawa H, Matsuda H. Controlled nicorandil administration for myocardial protection during coronary artery bypass grafting under cardiopulmonary bypass. J Cardiovasc Pharmacol 2001; 38: 21–28.Google Scholar
Chauhan S, Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P. Adenosine for cardioplegic induction: a comparison with St. Thomas solution. J Cardiothorac Vasc Anesth 2000; 14: 21–24.Google Scholar
Chambers DJ. Nicorandil cardioplegia or procaine cardioplegia? Eur J Cardiothorac Surg 2003; 24: 669–671.Google Scholar
Buckberg GD, Hottenrott CE. Ventricular fibrillation: its effect on myocardial flow distribution and performance. Ann Thorac Surg 1975; 20: 76–85.Google Scholar
Benoit MO, Paris M, Silleran J, Fiemeyer A, Moatti N. Cardiac troponin-I: its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Crit Care Med 2001; 29: 1880–1886.Google Scholar
Yasu T, Ikeda N, Ishizuka N et al. Nicorandil and leukocyte activation. J Cardiovasc Pharmacol 2002; 40: 684–692.Google Scholar
Wei XM, Heywood GJ, Di Girolamo N, Thomas PS. Nicorandil inhibits the release of TNF-alpha from a lymphocyte cell line and peripheral blood lymphocytes. Int Immunopharmacol 2003; 3: 1581–1588.Google Scholar
Lee TM, Lin MS, Tsai CH, Chang NC. Effect of ischemic preconditioning on regional release of inflammation markers. Clin Sci 2005: 109: 267–276.Google Scholar
Tomai F, Crea F, Gaspardone A et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700–705.Google Scholar
Cleveland Jr JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulphonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 1997; 96: 29–32.Google Scholar
Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531–537.Google Scholar
Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001; 37: 711–718.Google Scholar
Wilde AA, Janse MJ. Electrophysiological effects of ATP-sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994; 28: 16–21.Google Scholar
Kato K. Hemodynamic and clinical effects of an intravenous potassium channel opener – a review. Eur Heart J 1993; 14 (Suppl B): S40–S47.Google Scholar
Yadav R, Bhargava B, Aggarwal R et al. Acute haemodynamic effects of nicorandil in patients with chronic severe regurgitant valvular lesions. Ind Heart J 1998; 50: 173–178.Google Scholar
Kambara H, Tamaki S, Nakamura Y, Kawai C. Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function. Am J Cardiol 1989; 63: 56J–60J.Google Scholar
Qiu Y, Galinanes M, Hearse DJ. Protective effect of nicorandil as an additive to the solution for continuous warm cardioplegia. J Thorac Cardiovasc Surg 1995; 110: 1063–1072.Google Scholar
Li Y, Iguchi A, Tsuru Y, Nakame T, Satou K, Tabayashi K. Nicorandil pretreatment and improved myocardial protection during cold blood cardioplegia. Jpn J Thorac Cardiovasc Surg 2000; 48: 24–29.Google Scholar
Steensrud T, Nordhaug D, Elvenes OP, Korvald C, Sorlie DG. Superior myocardial protection with nicorandil cardioplegia. Eur J Cardiothorac Surg 2003; 5: 670–677.Google Scholar
Steensrud T, Nordhaug D, Husnes KV, Aghajani E, Sorlie DG. Replacing potassium with nicorandil in cold St. Thomas’ Hospital cardioplegia improves preservation of energetics and function in pig hearts. Ann Thorac Surg 2004; 77: 1391–1397.Google Scholar
Goldman L. Medical management of the patient undergoing cardiac surgery. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 5th edn. Philadelphia: WB Saunders Company, 1997: 1715–1740.